Drug Trial Radar · NCT07479797
Study Evaluating the Efficacy of KITE-753 Versus Axicabtagene Ciloleucel in Participants With Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy
Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
550
Planned (sponsor's estimate)
Start
May 22, 2026
Primary completion
May 2031
Study completion May 2031
Sponsor
- Lead sponsor
- Kite, A Gilead CompanyGilead Sciences (GILD)
- Sponsor type
- Industry
- First posted
- Mar 18, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical study is to compare the study drug KITE-753 versus axicabtagene ciloleucel (axi-cel) in adult participants with relapsed or refractory (r/r) large B-cell lymphoma (LBCL) after one prior line of therapy. The primary objective of this study is to evaluate the efficacy of KITE-753 versus axicabtagene ciloleucel.
Conditions
- Relapsed or Refractory Large B-cell Lymphoma
Interventions
KITE-753Drug
A single infusion of CAR-transduced autologous T cells administered as intravenous infusion.
Axicabtagene CiloleucelDrug
A single infusion of CAR-transduced autologous T cells administered as intravenous infusion.
FludarabineDrug
Administered intravenously
CyclophosphamideDrug
Administered intravenously
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of Participants in Complete Response (CR) at Month 6Time frame: Month 6
- Event-free survival (EFS)Time frame: Up to 36 months
Locations
42 sites in 9 countries. Site status is shown where the registry gives one.
City of Hope Arizona
Goodyear, Arizona
City of Hope (City of Hope National Medical Center, City of Hope Medical Center)
Duarte, California
Stanford University
Stanford, California
Colorado Blood Cancer Institute
Denver, Colorado
Yale University School of Medicine
New Haven, Connecticut
Moffitt Cancer Center
Tampa, Florida
Southeastern Regional Medical Center, Inc. dba City of Hope Atlanta
Newnan, Georgia
University of Illinois
Chicago, Illinois
City of Hope - Chicago
Zion, Illinois
University of Maryland St. Joseph Medical Center
Baltimore, Maryland
Washington University
St Louis, Missouri
Weill Cornell Medicine-NewYork-Presbyterian Hospital
New York, New York
Memorial Sloan Kettering Cancer Center
New York, New York
Montefiore Medical Center
The Bronx, New York
Novant Health Cancer Institute - Hematology
Charlotte, North Carolina
Henry-Joyce Cancer Clinic
Nashville, Tennessee
Tennessee Oncology, PLLC - Investigational Drug Services
Nashville, Tennessee
St. David's South Austin Medical Center
Austin, Texas
Inova Shar Cancer Institute
Fairfax, Virginia
Fred Hutchinson Cancer Center
Seattle, Washington
West Virginia University
Morgantown, West Virginia
Royal Prince Alfred Hospital
Camperdown, New South Wales, Australia
Concord Repatriation General Hospital
Sydney, New South Wales, Australia
Epworth Healthcare
East Melbourne, Victoria, Australia
Universitair Ziekenhuis Antwerpen
Edegem, Belgium
Universitair Ziekenhuis Gent
Ghent, Belgium
Jewish General Hospital
Montreal, Canada
McGill University Health Centre
Montreal, Canada
CHU de Québec, Hôpital de l'Enfant-Jésus
Québec, Canada
Hopital Saint Eloi
Montpellier, France
Universitatsklinikum Wurzburg
Würzburg, Germany
National Cancer Center Hospital
Tokyo, Japan
Toranomon Hospital
Tokyo, Japan
Hospital Clinic de Barcelona
Barcelona, Spain
Institut Catala d'Oncologia
Barcelona, Spain
Hospital General Universitario Gregorio Maranon
Madrid, Spain
Hospital Universitario 12 de Octubre
Madrid, Spain
Clinica Universidad de Navarra
Pamplona, Spain
Hospital Universitario de Salamanca
Salamanca, Spain
Cardiff and Vale University Health Board
Cardiff, United Kingdom
Showing 40 of 42 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.